A decline in both revenues (more than 10% year-over-year) and EPS (also down 10%) is practically guaranteed to put investors off. What may help see Pfizer through is its future. The trailing 12-month price/earnings ratio is a large 23.68, while the future P/E ratio comes back to earth with a current print of 14.65.
The most recent analysts’ calls on the stock are also positive:
- Bernstein maintained its Outperform rating and boosted the price target from $38 to $39
- Jefferies initiated coverage in mid-June with an Overweight rating and a price target of $45
- Piper Jaffray initiated coverage in early June, also with an Overweight rating and $45 price target
Pfizer shares were recently trading at around $34.15 in the mid-afternoon on Monday. The consensus analyst price target is $38.25, and the 52-week range is $27.51 to $35.53. Pfizer has a 3.3% dividend yield, and its market cap is about $210.4 billion.The company has been in a state of flux following the the Zoetis spin-off and the pending Hospira acquisition. Analysts appear to believe that the $15 billion Hospira deal will give Pfizer a shot in the arm once the acquisition is final.
ALSO READ: 9 States with the Most Dangerous Weather
Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.